解读肿瘤坏死因子拮抗剂应用中结核病的预防与管理专家共识  

Interpretation of expert position paper on tuberculosis prevention and management in tumor necrosis factor antagonist application

作　　者：薛勤[1] 汪年松[1] 

机构地区：[1]上海交通大学附属第六人民医院肾脏风湿科,上海200233

出　　处：《世界临床药物》2016年第8期505-507,共3页World Clinical Drug

基　　金：国家自然基金面上项目(编号:81270824);国家自然基金青年基金项目(编号:81400735);上海交通大学医学院转化医学基金(编号:152H2011);"十二五"国家科技支撑计划(编号:2013BAI02B01-01)

摘　　要：肿瘤坏死因子(TNF)拮抗剂可有效缓解风湿病患者的临床症状,改善患者的生活质量和预后。然而,该类药物与结核病(TB)的发病相关。我国TB发病率较高,需格外关注TNF拮抗剂应用过程中TB预防与管理问题。2013年8月发布的《肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识》,从高危群体筛查、检测方法、治疗及随访等方面对风湿病患者接受TNF拮抗剂治疗中TB的管理提出详细的推荐意见。本文简要解读其中与临床关系密切的重点部分。Tumor necrosis factor （TNF） antagonist can effectively relieve clinical symptoms and improve life quality and prognosis of rheumatism patients. However, some studies show that TNF antagonist is related to tuberculosis （TB）. China is one of the countries with high incidence of TB, so clinic should pay more attention to the prevention and management of TB when TNF antagonist is used. The released expert position paper of TB prevention and management in TNF application was published in August 2013. It provides a recommendation for TB management on rheumatism patients who received TNF antagonist treatment, to guide the TNF antagonist application in clinic. This review briefly interprets the key parts relate to clinic of the expert position paper.

关 键 词：肿瘤坏死因子(TNF)拮抗剂 风湿病 结核病(TB) 

分 类 号：R593.2[医药卫生—内科学] R52[医药卫生—临床医学]